GU Cancers 2019 | Sacituzumab govitecan and NKTR-214 plus nivolumab for bladder cancer

Arjun Balar

Speaking from the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Arjun Balar, MD, from NYU Langone Health Perlmutter Cancer Center, New York City, NY, discusses the promising results from the Phase I study with sacituzumab govitecan (NCT01631552), and the PIVOT-02 study (NCT02983045) looking at the novel combination of NKTR-214 with nivolumab for treating-bladder cancer resistant to checkpoint inhibitors.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter